CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC

Landmark trials in breast cancer.pptx

CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials - ScienceDirect

Consort diagram: EC-Doc: epirubicin/cyclophsophamide 4× followed by

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial - ScienceDirect

CONSORT trial fl ow diagram for MA.17 trial.

Cancers, Free Full-Text

CONSORT diagram: NSABP Protocols B-30, B-31, B-34, and B-38. BC=Breast

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial, Breast Cancer Research

CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials - ScienceDirect

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Alterations in immune cell phenotype and cytotoxic capacity in

View of Abemaciclib (Verzenio) Canadian Journal of Health Technologies

Frontiers Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II